Skip to main content

Table 3 Secondary parameters of the final model describing artemisinin population pharmacokinetics in healthy male Vietnamese subjects

From: Population pharmacokinetic properties of artemisinin in healthy male Vietnamese volunteers

Parameter

Treatment 1

Treatment 2

Treatment 3

Treatment 4

Cmax (ng/mL)

111 [45.2–183]

96.7 [52.1–169]

244 [133–479]

144 [58–200]

Tmax (h)

1.41 [0.762–2.06]

1.09 [0.773–2.28]

1.72 [1.12–3.65]

0.992 [0.628–1.90]

t1/2 (h)

1.97 [1.64–3.37]

1.80 [1.46–3.20]

1.93 [1.71–2.43]

2.02 [1.64–2.42]

AUC0–12 (ng × h/mL)

461 [144–651]

342 [178–624]

956 [462–1973]

462 [189–744]

AUC (ng × h/mL)

441 [472–146]

349 [181–642]

994 [468–2040]

467 [192–761]

  1. Secondary parameters estimated from the final model and values are presented as median [range]. C max is the maximum concentration and T max is the time to reach Cmax. t 1/2 is the estimated terminal elimination half-life. AUC 012 is the accumulated area under the concentration–time curve from time zero to 12 h after dose and AUC is the accumulated area under the concentration–time curve from time zero extrapolated to infinity. Treatment 1 was administrated as 160 mg micronized artemisinin, treatment 2 was 160 mg of the reference formulation of artemisinin, treatment 3 was 500 mg of the reference formulation of artemisinin and treatment 4 was 160 mg micronized artemisinin and 720 mg of piperaquine phosphate